מחיר רכישת החברה: Tiziana Life Sciences, Ltd. (TLSA)

The market price visualization for Tiziana Life Sciences (TLSA) on the GURU.Markets platform shows the enterprise value at 100.40. Tiziana Life Sciences focuses on developing targeted antibodies for oncology and severe inflammation. The approval of foralumab will provide the company with pricing power due to its unique nasal drug delivery method to the brain. Meanwhile, the company optimizes R&D costs by effectively outsourcing manufacturing processes to third-party contractors.
Tiziana Life Sciences (TLSA) - פילוחי מדדים ודוחות פיננסיים

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt to eliminate the impact of leverage. The current value of 100.40 on this enterprise value chart reflects Tiziana Life Sciences (TLSA) high dependence on existing reserves, which are rapidly depleting due to costly immunological developments, rendering the asset sensitive to liquidity shortages.